Midwest Clinical Research Center

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Depression4 trials
• Schizophrenia3 trials
• Bipolar disorder2 trials
• Essential tremor1 trial

Phase

• Phase 26 trials
• Phase 33 trials
• Phase 2/32 trials
• Phase 11 trial
• Phase 41 trial

Status

• Completed11 trials
• Terminated2 trials

Lead sponsor

• Biohaven Therapeutics Ltd.3 trials
• Biohaven Pharmaceuticals, Inc.2 trials
• Janssen Research & Development, LLC2 trials
• Jazz Pharmaceuticals2 trials
• Karuna Therapeutics, Inc., a Bristol Myers Squibb company1 trial
• and 3 more

Closed trials

• Completed

  Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

  NCT06423781· Phase 2· Biohaven Therapeutics Ltd.· Source

• Terminated

  BHV-7000 Open-Label Extension Bipolar Mania Study

  NCT06423794· Phase 2· Biohaven Therapeutics Ltd.· Source

• Completed

  BHV-7000 Acute Treatment of Bipolar Mania

  NCT06419582· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Completed

  A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

  NCT06254612· Phase 2· Sirtsei Pharmaceuticals, Inc.· Source

• Completed

  Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

  NCT06179108· Phase 2· LB Pharmaceuticals Inc.· Source

• Completed

  A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

  NCT05542264· Phase 1· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Completed

  A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

  NCT05455684· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of JZP150 in Adults With Posttraumatic Stress Disorder

  NCT05178316· Phase 2· Jazz Pharmaceuticals· Source

• Completed

  A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)

  NCT05122650· Phase 2· Jazz Pharmaceuticals· Source

• Completed

  An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

  NCT04820309· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Terminated

  Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

  NCT04708834· Phase 3· Biohaven Pharmaceuticals, Inc.· Source

• Completed

  A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

  NCT04599855· Phase 4· Janssen Research & Development, LLC· Source

• Completed

  Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder

  NCT03299166· Phase 2/3· Biohaven Pharmaceuticals, Inc.· Source